AEON Biopharma annual current ratio
2021
2022
2023
2024
2025
AEON Biopharma Current Ratio Growth & History (AEON)
AEON Biopharma's current ratio was 0.49 for fiscal 2025.
View full AEON Biopharma company overviewAEON Biopharma annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.49 | 0.38 | +338.42% |
| 2024 | 2024-12-31 | 0.11 | −0.36 | −76.43% |
| 2023 | 2023-12-31 | 0.48 | 0.36 | +300.21% |
| 2022 | 2022-12-31 | 0.12 | −0.88 | −88.09% |
| 2021 | 2021-12-31 | 1.00 | — | — |
AEON Biopharma quarterly current ratio
As of Dec 31, 2020
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.54 | −0.58 | −51.62% |
| Q1 2026 | 2026-03-31 | 0.99 | −0.43 | −30.34% |
| Q4 2025 | 2025-12-31 | 0.49 | 0.38 | +338.42% |
| Q3 2025 | 2025-09-30 | 0.90 | 0.68 | +307.52% |
| Q2 2025 | 2025-06-30 | 1.12 | 0.74 | +191.70% |
| Q1 2025 | 2025-03-31 | 1.43 | 1.27 | +810.94% |
| Q4 2024 | 2024-12-31 | 0.11 | −0.36 | −76.43% |
| Q3 2024 | 2024-09-30 | 0.22 | −0.97 | −81.47% |
| Q2 2024 | 2024-06-30 | 0.39 | 0.32 | +515.75% |
| Q1 2024 | 2024-03-31 | 0.16 | 0.06 | +69.52% |
| Q4 2023 | 2023-12-31 | 0.48 | 0.36 | +300.21% |
| Q3 2023 | 2023-09-30 | 1.19 | 1.07 | +867.67% |
| Q2 2023 | 2023-06-30 | 0.06 | −0.19 | −75.66% |
| Q1 2023 | 2023-03-31 | 0.09 | −0.56 | −85.90% |
| Q4 2022 | 2022-12-31 | 0.12 | −0.88 | −88.09% |
| Q3 2022 | 2022-09-30 | 0.12 | −4.48 | −97.32% |
| Q2 2022 | 2022-06-30 | 0.26 | −6.43 | −96.16% |
| Q1 2022 | 2022-03-31 | 0.65 | −3.91 | −85.67% |
| Q4 2021 | 2021-12-31 | 1.00 | −0.36 | −26.38% |
| Q3 2021 | 2021-09-30 | 4.60 | — | — |
| Q2 2021 | 2021-06-30 | 6.69 | — | — |
| Q1 2021 | 2021-03-31 | 4.57 | — | — |
| As of Dec 31, 2020 | 2020-12-31 | 1.36 | — | — |
AEON Biopharma current ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, AEON Biopharma's current ratio decreased from 1.00 to 0.49, a change of −0.51. The latest reported quarter, Q2 2026, shows 0.54.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AEON Biopharma source filings ↗